FDA Grants Fast Track Designation to AMG 510 for KRAS G12C+ NSCLC

Sep 9, 2019 – The FDA has granted a fast track designation to the investigational KRAS inhibitor AMG 510 for the treatment of patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have received prior treatment. The decision is based on updated phase I data that were recently presented during the 2019 World Conference on Lung Cancer, which showed that AMG 150 elicited a 100% disease control rate (DCR) at the target dose in evaluable patients … (leggi tutto)